newsfilter
← Latest News
GlobeNewswire·

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S.